Document is current

Article History

Received: 22 March 2024

Accepted: 22 July 2024

First Online: 6 August 2024

Declarations

:

: Revit Geva: Consultant for AstraZeneca, Roche, Bayer, MSD, Oncotest, and Pfizer; Leadership role with Pyxis; Shareholder/stockholder/stock options with Pyxis; Honoraria from AstraZeneca, Amgen, Janssen, Medison, Merck, MSD, Novartis, Pfizer, Takeda, and Roche; Travel/accommodation expenses from Medison and Merck. Maria Vieito: Consultant for Debiopharm Group, Roche, and TFS; Travel/ accommodation expenses from Merck, Roche, Serono. Ruth Perets: Consultant for Clexio Biosciences, Galmed Pharmaceuticals, IE therapeutics, and Simplivia; Honoraria from MSD and GSK; Travel/accommodation expenses from MSD. Emiliano Calvo: Employee of START; Leadership role with BeiGene, EORTC, Merus NV, Novartis, PharmaMar, Sanofi, and START; Shareholder/stockholder/stock options with Oncoart Associated and START; Honoraria from HM Hospitales Group; Consultant for Adcendo, Amunix, Anaveon, AstraZeneca/MedImmune, Bristol-Myers Squibb, Chugai Pharma, Diaccurate, Elevation Oncology, Ellipses Pharma, Genmab, Janssen-Cilag, MonTa, MSD Oncology, Nanobiotix, Nouscom, Novartis, OncoDNA, PharmaMar, Roche/Genentech, Servier, Syneos Health, T-Knife, and TargImmune Therapeutics; Research funding from START; President and Founder of Foundation INTHEOS (Investigational Therapeutics in Oncological Sciences); Member of Non-for-profit Foundation PharmaMar, Non-for-profit CRIS Cancer Foundation. Elena Garralda: Employee of NEXT Oncology; consultant or advisor to Alkermes, Anaveon, Boehringer Ingelheim, Ellipses Pharma, F-Star Therapeutics, Hengrui Therapeutics, Incyte, Janssen, MabDiscovery, Roche, Sanofi, Seattle Genetics, and Thermo Fisher Scientific; Speakers bureau of Eli Lilly, MSD, Novartis, Roche, Seagen, and Thermo Fisher Scientific; Recipient of numerous institutional research grants. Victor Moreno: Employee of START; Consultant for Bayer, BMS, Janssen Oncology, and Merck; Speaker bureau fees from Bayer; Research funding from Abbvie, ACEA Biosciences, Adaptimmune, Amgen, AstraZeneca, Bayer, BeiGene, Boehringer Ingelheim, BMS, Celgene, E-therapeutics, Eisai, GSK, Janssen, Menarini, Merck, Nanobiotix, Novartis, Pfizer, PharmaMar, PsiOxus Therapeutics, Puma Biotechnology, Regeneron, RigonTEC, Roche, Sanofi, Sierra Oncology, Synthon, Taiho Pharmaceutical, Takeda, Tesaro, and Transgene; Travel and accommodation expenses from Regeneron/Sanofi. Regina J. Brown, James G. Greger, Shujian Wu, Douglas Steinbach, Tsun-Wen Sheena Yao, Yu Cao, Josh Lauring, Ruchi Chaudhary, Jaymala Patel and Bharvin Patel: Employees of Janssen Research & Development and own stock/stock options in Johnson & Johnson. Jorge Ramon, Manuel Pedregal, Elena Corral, Bernard Doger and Jorge Bardina: No conflict of interest.

: This clinical study was conducted in accordance with the principles of the Declaration of Helsinki and local laws and regulations. The study protocol and all amendments were reviewed by the independent ethics committee and/or institutional review board for each study center.

: Written informed consent was provided by all patients before any study procedures took place.